DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Mok TSK, Wu Y-L, Kudaba I. et al.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet 2019;
393: 1819-1830
DOI: 10.1016/S0140-6736(18)32409-7.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.